ElectroCore has patented a method to treat inflammatory responses associated with coronaviruses by emitting electrical impulses near the vagus nerve. The treatment aims to reduce inflammation, bronchoconstriction, and abnormal blood clotting in post-COVID conditions. The method involves applying impulses transcutaneously on the neck. GlobalData’s report on ElectroCore gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights ElectroCore Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ElectroCore, Cardiac stimulation implants was a key innovation area identified from patents. ElectroCore's grant share as of February 2024 was 66%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of inflammatory response in covid-19 patients using electrical impulses

Source: United States Patent and Trademark Office (USPTO). Credit: ElectroCore Inc

A recently granted patent (Publication Number: US11894148B2) discloses a method for treating medical disorders associated with viruses in the coronaviridae family in patients. The method involves using a device to apply electrical impulses transcutaneously through the outer skin surface of the patient's neck to the vagus nerve. These impulses are aimed at reducing the levels of C-reactive protein in the patient's blood by at least 10 mg/L. The treatment paradigm includes applying the electrical impulse as a single dose ranging from 30 seconds to 5 minutes, 2 to 5 times per day, with each pulse having specific frequency and amplitude parameters.

Furthermore, the method outlined in the patent claims also targets the reduction of procalcitonin levels in the patient's blood, with specific reductions of at least 2 ng/L or 5 ng/L. Additionally, the electrical impulse is designed to inhibit the release of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-alpha. The device used for this treatment comprises electrodes and a housing with an energy source to generate the necessary electrical impulses. The method aims to not only reduce C-reactive protein levels by at least 25 mg/L but also decrease the constriction of smooth bronchial muscle. The impulses are delivered in bursts of 2-20 pulses with specific frequency ranges to achieve the desired therapeutic effects.

To know more about GlobalData’s detailed insights on ElectroCore, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.